Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Segment Operations
BSX logo

Boston Scientific Targets Growth with $14.5 Billion Penumbra Acquisition and 27% R&D Surge

BSX10-KFiling Date: 2/17/2026
Boston Scientific Corporation
Description

What this story covers

Boston Scientific's 2025 10-K reveals a high-growth strategy fueled by the $14.5 billion Penumbra acquisition and blockbuster Electrophysiology products. Despite $800 million in restructuring costs, the company achieved $13.8 billion in gross profit, signaling strong global momentum.

Story snapshot

CompanyBoston Scientific Corporation
TickerBSX
VariantStandard detailed
Duration11:56
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0000885725-26-000010
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in